Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Kura Oncology Inc is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Kura Oncology employs 116 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $11.78 |
|---|---|
| 52-week range | $12.02 - $36.27 |
| 50-day moving average | $14.84 |
| 200-day moving average | $19.56 |
| Wall St. target price | $37.57 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.92 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.78 from 2022-01-21
| 1 week (2022-01-12) | N/A |
|---|---|
| 1 month (2021-12-19) | N/A |
| 3 months (2021-10-22) | -32.92% |
| 6 months (2021-07-23) | -37.34% |
| 1 year (2021-01-22) | -65.74% |
|---|---|
| 2 years (2020-01-22) | -6.88% |
| 3 years (2019-01-22) | 15.47 |
| 5 years (2017-01-20) | 91.54% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.29% |
| Return on equity TTM | -29.49% |
| Profit margin | 0% |
| Book value | $8.03 |
| Market capitalisation | $907.8 million |
TTM: trailing 12 months
We're not expecting Kura Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $12.02 up to $36.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 1.5474. This would suggest that Kura Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.